NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 42 resultados LastUpdate Última actualización: 28/08/2016 [14:25:00] pdf PDF




Solicitudes de Patente publicadas en los últimos 30 días / Patent Applications published in the last 30 days



Página 1 de 2 nextPage   Mostrar por página


METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH MALIGNANT HEMATOLOGICAL DISEASE TO CHEMOTHERAPY TREATMENT AND METHODS OF TREATMENT OF SUCH DISEASE

Nº publicación: WO2016128523A1 18/08/2016

Solicitantes:
INSERM (INSTITUT NAT DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
UNIVERSIT\u00C9 PARIS DESCARTES [FR]
CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]
FOND IMAGINE [FR]
ASSIST PUBLIQUE-H\u00D4PITAUX DE PARIS (APHP) [FR]
UNIVERSIT\u00C9 DE NANTES [FR]
UNIVERSIT\u00C9 D'ANGERS [FR]
CENTRE HOSPITALIER UNIV D'ANGERS [FR]

Resumen de: WO2016128523A1

The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML).The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a chemotherapy treatment.



traducir


 

NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF

Nº publicación: WO2016127249A1 18/08/2016

Solicitantes:
UNIVERSIT\u00C9 DE MONTR\u00C9AL [CA]
RSEM LTD PARTNERSHIP [CA]

Resumen de: WO2016127249A1

Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.



traducir


 

Α CRYSTAL FORM OF IPI-145 AND PREPARATION METHOD THEREOF

Nº publicación: WO2016127844A1 18/08/2016

Solicitante:
CRYSTAL PHARMATECH CO LTD [CN]

Resumen de: WO2016127844A1

The present invention relates to an α crystal form of a formula (I) compound used for preparing a leukemia treatment drug and preparation method thereof. The α crystal form provided in the present invention has a better stability, solubility and hygroscopicity comply with pharmaceutical requirements. The α crystal form has a simple preparation method and a low manufacturing cost, and provides a significant value to future optimization and development of the drug.



traducir


 

Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma

Nº publicación: WO2016127848A1 18/08/2016

Solicitante:
SICHUAN JIUZHANG BIO-TECHNOLOGY CO LTD [CN]

Resumen de: CN104622864A

The invention aims to provide an application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma. Experiments show that the chlorogenic acid can activate CD4 T-lymphocytes and CD8 T-lymphocytes, and prevent and treat primary cutaneous T-cell lymphoma by taking the CD4 T-lymphocytes and the CD8 T-lymphocytes as targets. According to the invention, the chlorogenic acid is adopted for promoting the proliferation of T-lymphocytes of a body and activating the T-lymphocytes so as to achieve the purpose of treating primary cutaneous T-cell lymphoma. Meanwhile, the chlorogenic acid also can inhibit the proliferation of primary cutaneous T-cell lymphoma cells, and the inhibition effect of the chlorogenic acid is similar to the inhibition effect of interferon.



traducir


 

ANTITUMOR AGENT

Nº publicación: WO2016129633A1 18/08/2016

Solicitante:
PUBLIC UNIV CORP NAGOYA CITY UNIV [JP]

Resumen de: WO2016129633A1

The present invention provides a composition and method for treatment or prevention in a subject having a tumor (e.g., a brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, lymphoma, or the like) in which the TUG1 gene is expressed at a high level relative to normal tissue, the composition including as an active ingredient a nucleic acid for suppressing high-level expression of the TUG1 gene in tumor stem cells.



traducir


 

COMBINATION THERAPY USING A CD19-ADC AND VINCRISTINE

Nº publicación: WO2016130902A1 18/08/2016

Solicitante:
SEATTLE GENETICS INC [US]

Resumen de: WO2016130902A1

This invention relates to treatment of acute lymphoblastic leukemia.



traducir


 

Method for obtaining high-yield stable expression cell clone and antibody molecule obtained by method

Nº publicación: WO2016127954A1 18/08/2016

Solicitantes:
BIOTECH PHARMACEUTICAL CO LTD [CN]
CENTER OF MOLECULAR IMMUNOLOGY [CU]

Resumen de: CN104651314A

The invention discloses a method for obtaining a recombinant myeloma cell clone in a protein-free culture medium. The method includes recombining a myeloma cell line, the process from the serum-free medium to the protein-free culture medium cannot be finished or can be finished with a long time, and the antibody yield is reduced due to the existence of the non-growth cell population. The method includes the gradual adapting process from low concentration to high concentration in the protein-free culture medium. The phenotypic adaptation cultured with high cell density in the protein-free culture medium is along with the increases of the recombinant antibody molecule secretion rate and the high-yield stable expression cell clone percentage. A humanized anti-NeuGcGM3 14F7h recombinant antibody can be prepared according to the cell clone disclosed in the invention. Furthermore, the attributive character of the humanized anti-NeuGcGM3 recombinant antibody14F7hare is also disclosed in the invention.



traducir


 

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Nº publicación: WO2016130952A1 18/08/2016

Solicitante:
IMAGO BIOSCIENCES INC [US]

Resumen de: WO2016130952A1

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.



traducir


 

TSPAN 33 IS A CANDIDATE FOR ANTIBODY TARGETED THERAPY FOR THE TREATMENT OF B CELL HODGKIN LYMPHOMAS

Nº publicación: US2016237152A1 18/08/2016

Solicitantes:
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
UNIV AUTONOMA DE NUEVO LE\u00D3N [MX]

Resumen de: WO2014100746A2

A method of treating a disease associated with activated B lymphocytes expressing Tetraspanin 33 (TSPAN33/BAAM). The disease can be, for example, lymphoma or an immune disease. The method includes administering an anti-TSPAN33/BAAM antibody to a patient in need of such treatment in an amount effective to treat the disease. Methods of purifying activated B cells and identifying activated and/or diseased B cells are also provided.



traducir


 

HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS

Nº publicación: US2016235679A1 18/08/2016

Solicitante:
ORSENIX BV [US]

Resumen de: WO2016123603A2

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplasia syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.



traducir


 

CHIMERIC ANTIGEN RECEPTOR

Nº publicación: US2016237139A1 18/08/2016

Solicitante:
UCL BUSINESS PLC [GB]

Resumen de: WO2015052538A1

The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.



traducir


 

LEUKEMIA STEM CELL TARGETING LIGANDS AND METHODS OF USE

Nº publicación: US2016237118A1 18/08/2016

Solicitante:
THE REGENTS OF THE UNIV OF CALIFORNIA [US]

Resumen de: WO2013009690A2

The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.



traducir


 

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Nº publicación: US2016237043A1 18/08/2016

Solicitante:
IMAGO BIOSCIENCES INC [US]

Resumen de: WO2016130952A1

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.



traducir


 

INHIBITORS OF MYELOID LEUKEMIA CELL GROWTH AND RELATED METHODS

Nº publicación: WO2016130816A1 18/08/2016

Solicitante:
THE REGENTS OF THE UNIV OF MICHIGAN [US]

Resumen de: WO2016130816A1

Methods of treatment using inhibitors of myeloid leukemia cell growth are provided. Such methods include, but are not limited to, methods of treating myeloid leukemia (e.g., promyelocytic leukemia, acute myeloid leukemia). Such inhibitors of myeloid leukemia cell growth include, but are not limited to, pharmaceutical compositions including a cis- derivative(s) of retinoic acid (e.g., pinacolyl 9-cw-retinoate, (2E, 4E, 6Z, 8E)-3,3-Dimethyl-2- xo-l-butyl 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-l-yl)nonatetraenoate (MDI 301)). Related kits and compositions are further provided.



traducir


 

HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma

Nº publicación: EP3054953A1 17/08/2016

Solicitante:
ACETYLON PHARMACEUTICALS INC [US]

Resumen de: US2015105383A1

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor.



traducir


 

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA

Nº publicación: EP3054954A1 17/08/2016

Solicitantes:
ACETYLON PHARMACEUTICALS INC [US]
MOFFITT CANCER CT [US]

Resumen de: US2015105409A1

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor.



traducir


 

GENETICALLY MODIFIED MICE AND ENGRAFTMENT

Nº publicación: EP3056082A1 17/08/2016

Solicitantes:
REGENERON PHARMA [US]
UNIV YALE [US]
INST RES IN BIOMEDICINE IRB [CH]

Resumen de: WO2011044050A2

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.



traducir


 

MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS

Nº publicación: EP3056514A1 17/08/2016

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2009091547A1

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.



traducir


 

MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS

Nº publicación: EP3056515A1 17/08/2016

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2009091547A1

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.



traducir


 

PYRAZOLONE COMPOUNDS AND USES THEREOF

Nº publicación: AU2015217450A1 11/08/2016

Solicitante:
INCEPTION 2 INC

Resumen de: WO2015123133A1

The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.



traducir


 

AN ANTI-LEUKEMIC AGENT USEFUL FOR INDUCING DIFFERENTIATION IN MYELOID LEUKEMIA CELLS

Nº publicación: US2016228410A1 11/08/2016

Solicitantes:
COUNCIL SCIENT IND RES [IN]
COUNCIL OF SCIENTICFIC & IND RES [IN]

Resumen de: WO2015044950A1

The present invention provides the compound Ormeloxifene [3, 4-trans-2,2-dimethyl-3-phenyl-4-p- (beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like C/EBPa and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (GCSFr). Differentiated cells having neutrophil like morphology were observed when treated with 1.0 uM to 7.5 uM ORM which clearly indicates that ORM can induce differentiation in myeloid leukemia cells. At higher doses (5uM to 7.5uM) there is early onset of myeloid differentiation ( 24 to 48h ) with reduced no. of cells which is likely due to apoptotic effects of ORM at higher does. In contrary, lower doses (1uM) induce differentiation after longer duration (6-15days) with quite reduced apoptotic effect.



traducir


 

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC MYELOID LEUKEMIA AND METHOD USING THE SAME

Nº publicación: WO2016126028A1 11/08/2016

Solicitante:
MEDPACTO INC [KR]

Resumen de: WO2016126028A1

Provided are a pharmaceutical composition for preventing or treating chronic myeloid leukemia and a method of preventing or treating chronic myeloid leukemia using the same, thereby being effectively applied to the prevention or treatment of chronic myeloid leukemia.



traducir


 

METHOD OF TARGETED GENE DELIVERY USING VIRAL VECTORS

Nº publicación: US2016222409A1 04/08/2016

Solicitante:
CALIFORNIA INST OF TECHN [US]

Resumen de: CA2611056A1

Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.



traducir


 

PROGNOSTIC METHODS, COMPOSITIONS AND KITS FOR PREDICTION OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) RELAPSE

Nº publicación: US2016222464A1 04/08/2016

Solicitante:
MOR RES APPLICATIONS LTD [IL]

Resumen de: US2016222464A1

The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.



traducir


 

SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF

Nº publicación: US2016221994A1 04/08/2016

Solicitante:
KARYOPHARM THERAPEUTICS INC [US]

Resumen de: WO2014085607A1

The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.


traducir



 

Página 1 de 2 nextPage Mostrar por página

Volver